Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
AiCuris
AiCuris
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
AiCuris initiates clinical development of AIC499, a novel resistance-breaking antibiotic
Programme supported by the Innovative Medicines Initiative
You need to be a subscriber to read this article.
Click here
to find out more.
Research & Development
Can new discoveries prevent an antibiotic Armageddon?
Governments are waking up to the catastrophe of drug resistance and healthcare without antibiotics. But is extra funding the answer or could the pharma industry be doing more?
Research & Development
COMBACTE-MAGNET project aims to stimulate antibiotic development in Europe
Seven-year project brings together 33 European academic partners and five pharmaceutical companies
Regulatory
Antiviral agent – letermovir
Cytomegalovirus (CMV) can cause severe difficulties in patients with compromised immune systems, such as people with HIV infection or those who are undergoing organ or bone marrow transplantation
Subscribe now